Gareth J. Morgan

Research interests

Publications

• International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

  Journal of Clinical Oncology · 2025 · https://doi.org/10.1200/jco-24-01893

• The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report

  The Lancet · 2019 · 10.1016/s0140-6736(18)32822-8

• Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30687-9

• A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0196-8

• Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

  Blood · 2018 · https://doi.org/10.1182/blood-2018-03-840132

• Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

  Nature Communications · 2017 · https://doi.org/10.1038/s41467-017-00296-y

• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.2267

• Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.59.1503

• International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2013.48.7934

• International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.47.7901

• Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.199

• Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.2119

• The genetic architecture of multiple myeloma

  Nature reviews. Cancer · 2012 · https://doi.org/10.1038/nrc3257

• Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

  Leukemia · 2012 · https://doi.org/10.1038/leu.2012.282

• The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

  Blood · 2011 · https://doi.org/10.1182/blood-2011-06-357038

• Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

  Blood · 2011 · https://doi.org/10.1182/blood-2011-06-358812

• A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.204

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

  Blood · 2010 · https://doi.org/10.1182/blood-2010-04-279596

• First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)62051-x

• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  Leukemia · 2009 · https://doi.org/10.1038/leu.2009.174

• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

  Leukemia · 2008 · https://doi.org/10.1038/leu.2008.307

• Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

  Leukemia · 2007 · 10.1038/sj.leu.2405062

• International uniform response criteria for multiple myeloma

  Leukemia · 2006 · 10.1038/sj.leu.2404284

• International Staging System for Multiple Myeloma

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.04.242

• Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.03.2086

• Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium

  The Lancet Oncology · 2005 · https://doi.org/10.1016/s1470-2045(05)70434-4

• High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

  New England Journal of Medicine · 2003 · https://doi.org/10.1056/nejmoa022340

• Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

  Leukemia · 2003 · https://doi.org/10.1038/sj.leu.2403202

• Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

  Blood · 2001 · https://doi.org/10.1182/blood.v98.1.210

Current projects

No projects listed.